Emerging Markets

Innovation is a critical tool in the global fight against tuberculosis (TB), an infectious disease that primarily affects the poor and vulnerable and ranks among the top 10 causes of death in the world. The Center for Global Development and the Office of Health Economics are proposing a new innovation model to bring better TB drugs to market. We call it the “Market-Driven, Value-Based Advance Commitment,” or MVAC for short.

The Center for Global Development and the Office of Health Economics are working on a new approach to drive the next generation of investment for better tuberculosis treatment. Our market-focused approach puts Brazil, Russia, India, China, and South Africa (the BRICS) governments in the driver’s seat—empowering them to send a powerful signal to private-sector pharmaceutical companies about the innovation they value and at the kind of price they are willing to consider.

OHE Consulting produces a report critiquing a paper by Hill et al. (2018) on estimated costs of production for the WHO Essential Medicines List.

Just published in BMJ Open: The effect of religion on the perception of health states among adults in the United Arab Emirates

The fourth annual meeting of the HTAi Asia Policy Forum was held in November 2016. OHE produced Background Briefing Papers for each of these four meetings covering a variety of topics relevant to the development of HTA in Asia, all of which are now available. This post contains a summary of each report.

OHE has published a new report discussing a framework to help middle-income countries efficiently identify medicines for formulary inclusion. A second publication applies this framework to the Mexican decision making system as a case study.

The Spanish Health Economics Association (AES) Conference was held at the University of Murcia, 15-18th June 2016. The topic of the meeting was “Reforms under the microscope”. Several members of the OHE team attended and contributed to the conference; this post summarises their activity.

This post summarises OHE’s activities at this year’s ISPOR Latin America conference in Santiago, September 2015. Topics include policy options for formulary development in middle-income countries, and role of HTA in definition of health benefit plans.

This post summarises OHE’s activities at the upcoming HTAi meeting in Oslo, June 2015. Topics include the effect of NICE decisions abroad, a framework for developing formularies in MICs, a new drug development paradigm, and a comparison of EQ-5D-5L and EQ-5D-3L.

Just published in Health Economics is an article by OHE’s Adrian Towse and others on pharmaceutical pricing in middle and low income countries (MLICs).

Pages

Subscribe to RSS - Emerging Markets